Please provide your email address to receive an email when new articles are posted on . A urinary DNA methylation test outperformed the nuclear matrix protein 22 test or urine cytology test.

A noninvasive urinary DNA methylation test demonstrated high sensitivity for detecting high-grade or invasive bladder cancer. A urinary DNA methylation test displayed superior sensitivity for ...

Active surveillance is noninferior to BCG induction therapy for invasive relapse-free survival in patients with high-grade T1 bladder cancer with no residual tumor on second TURBT. For patients with ...

Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBCBCG-unresponsive patients achieved an 80% CR ...

TAR-200 demonstrated high DFS and bladder preservation rates in BCG-unresponsive, high-risk non-muscle-invasive bladder cancer with papillary-only disease. The phase 2b SunRISe-1 study showed over 80% ...

A urinary DNA methylation test demonstrated high sensitivity and specificity for detecting high-grade or invasive bladder cancer, outperforming both nuclear matrix protein 22 (NMP22) and urine ...

When a doctor suspects bladder cancer, they will order a series of tests which may include urine tests (urinalysis or urine ...

Shares of Relmada Therapeutics RLMD rallied 42% in a week after the company announced positive 12-month interim data from its ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...

When you learn you have bladder cancer, it’s only natural to ask: "Can I survive this, for how long, and can I expect to be cured?" You may have searched online for survival rate information. These ...